Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome (FCS). The study revealed that the monthly administration of olezarsen…
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the ongoing conflict and identify necessary steps for its restoration. The…
AstraZeneca’s Imfinzi Shows Significant Improvement in Survival Rates for Limited-Stage Small Cell Lung Cancer Patients A recent Phase III trial, ADRIATIC, revealed promising outcomes for AstraZeneca’s Imfinzi (durvalumab) in treating patients with limited-stage small cell lung cancer (LS-SCLC). The trial…
Bristol Myers Squibb (NYSE: BMY) has unveiled its 2023 Environmental, Social, and Governance (ESG) Report, spotlighting significant progress, a refined strategy, and ambitious goals in its ESG initiatives. Rooted in its mission to pioneer innovative medicines aiding patients in overcoming…
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been officially accepted in the United States. This application targets the treatment of adult patients grappling with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC…
The CVS Health® (NYSE: CVS) today announced more than $3 million in new grants to support organizations in Phoenix working to increase equitable access to health care, address social determinants of health and educate the community on the effects of air…
Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations: Brazil, India, Thailand, and the United Kingdom. These new grants…
Roche, a leading healthcare company (SIX: RO, ROG; OTCQX: RHHBY), has announced today the approval by the U.S. Food and Drug Administration (FDA) for its cobas® Malaria test, designed for use on the cobas® 6800/8800 Systems. This milestone marks the…
Merck, also known as MSD outside of the United States and Canada, has announced today that the European Commission (EC) has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy. This approval allows its use in combination with platinum-containing chemotherapy as neoadjuvant…
Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk, branded as WINREVAIR™ in the U.S., for injection in 45mg and 60mg doses. This…
GenSight Biologics, a biopharmaceutical company listed on Euronext under the ticker symbol SIGHT and ISIN FR0013183985, eligible for PEA-PME, has disclosed its consolidated financial performance for the full year 2023. This report, approved by the Board of Directors on March…
The “2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report” has been added to ResearchAndMarkets.com’s offering. The landscape of biopharmaceutical clinical development is in a constant state of flux and progression. While major global Contract Research Organizations (CROs) cater to a significant portion…
